A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

NCT01773070 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: ABT-450/ritonavir
DRUG: ABT-333
DRUG: ABT-267

Sponsor

AbbVie (prior sponsor, Abbott)